

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	PMC	Journals	Bo	
Search	PubMed	<input type="checkbox"/> for						Go	Clear
<input checked="" type="checkbox"/> Links	Preview/Index	History	Clipboard	Details					
Display	Abstract	<input type="checkbox"/>	Show: 20	<input type="checkbox"/>	Sort	<input type="checkbox"/>	Send to	Text	<input type="checkbox"/>

Entrez PubMed

☐ 1: AIDS Res Hum Retroviruses. 1997 Sep
20;13(14):1187-94.

[Related Articles, Links](#)

PubMed Services


Induction of mucosal and systemic responses against human immunodeficiency virus type 1 glycoprotein 120 in mice after oral immunization with a single dose of a Salmonella-HIV vector.

Wu S, Pascual DW, Lewis GK, Hone DM.

Division of Infectious Diseases and Gastroenterology, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21202, USA.

Related Resources

Previous studies from our group showed that a Salmonella-HIV vector vaccine that expressed recombinant HIV-1 envelope protein gp120 stably in the vector cytoplasm elicited type 1 helper T cell (Th1) responses to gp120. Despite the promise of such vaccines, a major limitation in their use was that multiple immunizations were required to elicit even small responses. For this reason, we sought a modified vector configuration that would induce more potent gp120-specific T cell responses exhibiting a broader spectrum of effector functions after a single inoculation. In this article we describe the construction and immunogenicity of a Salmonella-HIV vector that displays a truncated derivative of HIV-1 (IIIB) envelope in the periplasm of the vector. A single oral dose of this Salmonella vector, called H683(pW58-asd+), generated a gp120-specific proliferation response in the spleen 14 days after immunization. In agreement with our previous findings, the gp120-specific splenic CD4+ T cells elicited by H683(pW58-asd+) displayed a Th1 phenotype; however, gp120-specific splenic CD4+ Th2 cells were also evident. In addition, this strain induced strong gp120-specific IgA antibody-secreting cell (ASC) responses in the intestinal lamina propria and mesenteric lymph nodes. As many as 2% of the total lamina propria and mesenteric lymph node IgA ASCs were found to be specific for gp120 28 days after a single oral dose of H683(pW57-asd+). Because the proliferative response following a single dose of H683(pW58-asd+) was comparable to that seen previously after three doses of an analogous construct expressing recombinant gp120 in the cytoplasm, these observations suggest that Salmonella-vectored secreted HIV-1 antigens elicit higher T cell responses than their cytoplasmically bound analogs.



Entrez	PubMed	Nucleotide	Protein	Genome	Structure	PMC	Journals	Bo
Search	PubMed	<input type="checkbox"/> for					Go	Clear
<input checked="" type="checkbox"/> Limits	Preview/index	History	Clipboard	Details				
Display	Abstract	<input type="checkbox"/> Show: 20	<input type="checkbox"/> Sort	<input type="checkbox"/> Send to	Text	<input type="checkbox"/>		

☐ 1: J Virol. 1994 Mar;68(3):1624-32.

Related Articles, Links

Entrez PubMed

QR 355.765 WPF
Mucosal model of genital immunization in male rhesus macaques with a recombinant simian immunodeficiency virus p27 antigen.


PubMed Services

Lehner T, Tao L, Panagiotidi C, Klavinskis LS, Brookes R, Hussain L, Meyers N, Adams SE, Gearing AJ, Bergmeier LA.

Division of Immunology, United Medical School, Guy's Hospital, London, United Kingdom.

Related Resources

Human immunodeficiency virus (HIV) can be transmitted through infected seminal fluid or vaginal or rectal secretions during heterosexual or homosexual intercourse. To prevent mucosal transmission and spread to the regional lymph nodes, an effective vaccine may need to stimulate immune responses at the genitourinary mucosa. In this study, we have developed a mucosal model of genital immunization in male rhesus macaques, by topical urethral immunization with recombinant simian immunodeficiency virus p27gag, expressed as a hybrid Ty virus-like particle (Ty-VLP) and covalently linked to cholera toxin B subunit. This treatment was augmented by oral immunization with the same vaccine but with added killed cholera vibrios. Polymeric secretory immunoglobulin A (sIgA) and IgG antibodies to p27 were induced in urethral secretions, urine, and seminal fluid. This raises the possibility that the antibodies may function as a primary mucosal defense barrier against SIV (HIV) infection. The regional lymph nodes which constitute the genital-associated lymphoid tissue contained p27-specific CD4⁺ proliferative and helper T cells for antibody synthesis by B cells, which may function as a secondary immune barrier to infection. Blood and splenic lymphocytes also showed p27-sensitized CD4⁺ T cells and B cells in addition to serum IgG and IgA p27-specific antibodies; this constitutes a third level of immunity against dissemination of the virus. A comparison of genito-oral with recto-oral and intramuscular routes of immunization suggests that only genito-oral immunization elicits specific sIgA and IgG antibodies in the urine, urethra, and seminal fluid. Both genito-oral and recto-oral immunizations induced T-cell and B-cell immune responses in regional lymph nodes, with preferential IgA antibody synthesis. The mucosal route of immunization may prevent not only virus transmission through the genital mucosa but also dissemination and latency of the virus in the draining lymph nodes.



Entrez	PubMed	Nucleotide	Protein	Genome	Structure	PMC	Journals	Bo
Search	PubMed	<input type="text" value="for"/>					Go	Clear
		<input checked="" type="checkbox"/> Limits	Preview/Index	History	Clipboard	Details		
Display		Abstract	<input type="text" value="20"/>	Show	Sort	<input type="text" value="Text"/>	Send to	

☐ 1: AIDS Res Hum Retroviruses. 1992 Aug;8(8):1379. [Related Articles, Links](#)

Entrez PubMed

RC 607, A26, A35
Oral priming followed by parenteral immunization with HIV-immunosomes induce HIV-1-specific salivary and circulatory IgA in mice and rabbits.

PubMed Services

Thibodeau L, Tremblay C, Lachapelle L.

AIDS Laboratory, Institut Armand Frappier, University of Quebec, Laval, Canada.


PMID: 1466960 [PubMed - indexed for MEDLINE]

Related Resources

Display	Abstract	<input type="text" value="20"/>	Show	Sort	<input type="text" value="Text"/>	Send to	
---------	----------	---------------------------------	------	------	-----------------------------------	---------	--

[Write to the Help Desk](#)
[NCBI | NLM | NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act | Disclaimer](#)

Get it? (PDF) (PDF) (PDF)



Entrez	PubMed	Nucleotide	Protein	Genome	Structure	PMC	Journals	Bo	
Search	PubMed	<input type="checkbox"/> for						Go	Clear
		<input checked="" type="checkbox"/> Links	Preview/index	History	Clipboard	Details			
Display		Abstract	<input type="checkbox"/>	Show: 20	<input type="checkbox"/>	Sort	<input type="checkbox"/>	Send to	Text

☒ 1: AIDS. 1994 Jun;8(6):779-85.

Related Articles, Links

RC 607. A26.A344


Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects.

Lewis DJ, Gilks CF, Ojoo S, Castello-Branco LR, Dougan G, Evans MR, McDermott S, Griffin GE.

Division of Communicable Diseases, St George's Hospital Medical School, London, UK.

OBJECTIVE: To determine the effect of HIV-1 infection on immunoglobulin (Ig) G and IgA antibody response and circulating antibody forming cell response to oral immunization with the B subunit of cholera toxin. **DESIGN:** Healthy UK volunteers, and HIV-1-positive UK and Kenyan volunteers at different clinical stages of HIV-1 infection received two oral immunizations. CD4+ T cells, serum beta 2-microglobulin and neopterin were measured as surrogate markers of disease stage, and correlated with immunization response. **METHODS:** Serum antitoxin IgG and IgA measured by enzyme-linked immunosorbent assay and antitoxin IgG, IgA and IgM antibody-forming cells detected by enzyme-linked immunospot assay at different times after two oral immunizations. **RESULTS:** UK HIV-positive volunteers (mean CD4+ T cell count, $52 \times 10(6)/l$) responded poorly to primary and booster immunization. HIV-infected Kenyans ($752 \times 10(6)/l$ CD4+ T cells) had a significant primary and booster antibody response, whereas those with a mean CD4+ T cell count $186 \times 10(6)/l$ had an insignificant primary, but significant booster response. Two oral immunizations induced antibody responses in HIV-positive Kenyan groups (who may have prior immunity from exposure to environmental bacterial toxins) of similar or greater magnitude to healthy UK volunteers. **CONCLUSIONS:** Mucosal immunization may recall immune memory and be of benefit in early and moderately advanced clinical HIV disease. The findings have important clinical implications in that mucosally targeted vaccines are potentially useful in this group of patients.

PMID: 8086136 [PubMed - indexed for MEDLINE]



Entrez	PubMed	Nucleotide	Protein	Genome	Structure	PMC	Journals	Books
Search	PubMed	<input type="checkbox"/> for					Go	Clear
<input checked="" type="checkbox"/> Limits	Preview/Index	History	Clipboard	Details				
Display	Abstract	<input type="checkbox"/> Show: 20	<input type="checkbox"/> Sort	<input type="checkbox"/> Send to	Text			

☒ 1: Oral Dis. 1997 May;3 Suppl 1:S79-84.

[Related Articles, Links](#)

[Entrez PubMed](#)

Salivary and mucosal immune responses to HIV and its co-pathogens.

Challacombe SJ, Sweet SP.

[PubMed Services](#)


Department of Oral Medicine and Pathology, UMDS Guy's Hospital, London, UK.



[Related Resources](#)

The profound effects that HIV induces in systemic immunity have been well characterised, but the situation with regard to mucosal immune responses is less clear. Oral cavity fluids have been used as a marker of the mucosal immune system. Whole and parotid saliva IgA, IgA1 and IgA2 concentrations have been found to be lower in both HIV infection and AIDS subjects, whereas serum IgA and IgA subclasses are markedly raised, suggesting a dichotomy between systemic and secretory immunity. Salivary antibodies to HIV can be readily detected and secretory IgA antibody can be neutralising to some strains of HIV. HIV vaccines can also induce antibody responses in saliva, but vaccination routes other than parenteral immunisation are needed. Antibody responses to oral microbes have also been studied and it has been shown that IgA, IgA1 and IgA2 subclass antibody titres to *Candida albicans* and to *Streptococcus mutans* are increased in whole or parotid saliva from HIV patients, but reduced in AIDS patients, suggesting a compensatory response which is overcome with progressive immunodeficiency. The avidity of salivary IgA antibodies to *Candida* in HIV seems unimpaired, whereas relative avidities of serum antibodies in HIV patients with candidiasis are lowered. Non-specific factors which may inhibit *Candida* and other opportunist pathogens are also found in saliva. The candidacidal, myelomonocytic protein calprotectin is present in saliva at levels which are biologically active, although levels are lowered in HIV infection. Overall, HIV infection appears to be associated with dysregulation of a number of immune factors at the mucosal surface, but the ability of patients with HIV infection to mount specific antibody secretory responses seems to be relatively intact until late in infection.

Publication Types:

- Review
- Review, Tutorial



Entrez	PubMed	Nucleotide	Protein	Genome	Structure	PMC	Journals	
Search	PubMed	 for					Preview	Go
		 Limits	Preview/index	History		Clipboard		Details

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.

Entrez PubMed

Search	Most Recent Queries	Time	Result
#30	Related Articles for PubMed (Select 9573261)	11:27:04	<u>186</u>
#26	Search HIV AND IgA AND vaccine AND mucosal Field: Title/Abstract, Limits: Publication Date to 1998/06/26	11:26:30	<u>21</u>
#27	Search #26 AND #1 Field: Title/Abstract, Limits: Publication Date to 1998/06/26	11:19:24	<u>6</u>
#25	Search HIV AND IgA AND vaccine AND mucous Field: Title/Abstract, Limits: Publication Date to 1998/06/26	11:15:11	<u>0</u>
#24	Search HIV AND IgA AND secretory AND vaccine AND mucous Field: Title/Abstract, Limits: Publication Date to 1998/06/26	11:13:12	<u>0</u>
#21	Search HIV AND IgA AND secretory AND vaccine AND oral Field: Title/Abstract, Limits: Publication Date to 1998/06/26	11:10:28	<u>4</u>
#20	Search HIV AND IgA AND secretory AND vaccine Field: Title/Abstract, Limits: Publication Date to 1998/06/26	11:10:11	<u>10</u>
#19	Search HIV AND buccal AND vaccine Field: Title/Abstract, Limits: Publication Date to 1998/06/26	11:09:51	<u>0</u>
#18	Search HIV-1 AND buccal AND vaccine Field: Title/Abstract, Limits: Publication Date to 1998/06/26	11:09:47	<u>0</u>
#17	Search HIV-1 AND Iga AND buccal AND vaccine Field: Title/Abstract, Limits: Publication Date to 1998/06/26	11:09:40	<u>0</u>
#16	Search HIV-1 AND Iga AND buccal Field: Title/Abstract, Limits: Publication Date to 1998/06/26	11:09:28	<u>1</u>
#14	Related Articles for PubMed (Select 1466960)	11:06:09	<u>113</u>
#2	Search HIV AND Iga AND oral Field: Title/Abstract, Limits: Publication Date to 1998/06/26	11:04:40	<u>38</u>

PubMed Services

Related Resources

#5 **Related Articles** for PubMed (Select **7585151**)10:51:51 205#1 Search **HIV AND Iga AND oral**10:48:15 93[Clear History](#)[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act](#) | [Disclaimer](#)

0-10-0007-001-00

WEST Search History

DATE: Thursday, October 23, 2003

Set Name Query
side by side

Hit Count Set Name
result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR

L4	L3 and secretory with (antibody or IgA or immunoglobulin\$3)	24	L4
L3	L1 and (HIV or human adj immunodeficiency) same gp160	74	L3
L2	L1 and (HIV or human adj immunodeficiency) (immunogen\$4 or vaccine or antigen) same (buccal or cheek or floor adj3 mouth or oral) and (IgA or immunoglobulin adj "a" or immunoglobulin-A)	583	L2
L1		1347	L1

END OF SEARCH HISTORY